Forum Financial Management LP grew its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 45.0% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 3,192 shares of the medical research company's stock after acquiring an additional 991 shares during the quarter. Forum Financial Management LP's holdings in Thermo Fisher Scientific were worth $1,661,000 as of its most recent SEC filing.
Other institutional investors also recently modified their holdings of the company. Cypress Advisory Group LLC acquired a new position in Thermo Fisher Scientific during the fourth quarter worth about $253,000. Intact Investment Management Inc. raised its stake in Thermo Fisher Scientific by 34.0% during the fourth quarter. Intact Investment Management Inc. now owns 2,600 shares of the medical research company's stock worth $1,353,000 after acquiring an additional 660 shares in the last quarter. Purkiss Capital Advisors LLC acquired a new position in Thermo Fisher Scientific during the fourth quarter worth about $1,121,000. Fifth Third Bancorp raised its stake in Thermo Fisher Scientific by 11.6% during the fourth quarter. Fifth Third Bancorp now owns 335,053 shares of the medical research company's stock worth $174,305,000 after acquiring an additional 34,917 shares in the last quarter. Finally, Independence Bank of Kentucky raised its stake in Thermo Fisher Scientific by 21.0% during the fourth quarter. Independence Bank of Kentucky now owns 3,825 shares of the medical research company's stock worth $1,990,000 after acquiring an additional 663 shares in the last quarter. Institutional investors own 89.23% of the company's stock.
Insider Activity at Thermo Fisher Scientific
In other news, SVP Michael A. Boxer sold 3,775 shares of Thermo Fisher Scientific stock in a transaction on Monday, March 10th. The stock was sold at an average price of $532.52, for a total transaction of $2,010,263.00. Following the sale, the senior vice president now directly owns 10,816 shares in the company, valued at $5,759,736.32. The trade was a 25.87% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Marc N. Casper sold 10,000 shares of Thermo Fisher Scientific stock in a transaction dated Tuesday, March 4th. The stock was sold at an average price of $516.67, for a total value of $5,166,700.00. Following the completion of the sale, the chief executive officer now directly owns 115,174 shares of the company's stock, valued at approximately $59,506,950.58. This trade represents a 7.99% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 14,075 shares of company stock valued at $7,305,942. 0.33% of the stock is owned by insiders.
Analyst Upgrades and Downgrades
TMO has been the subject of several recent research reports. Raymond James reaffirmed an "outperform" rating and issued a $667.00 price objective (up previously from $650.00) on shares of Thermo Fisher Scientific in a research note on Monday, February 3rd. Citigroup lowered their price objective on Thermo Fisher Scientific from $650.00 to $570.00 and set a "neutral" rating for the company in a research note on Tuesday, March 4th. Royal Bank of Canada lowered their price objective on Thermo Fisher Scientific from $651.00 to $637.00 and set an "outperform" rating for the company in a research note on Thursday, April 24th. Barclays reduced their target price on Thermo Fisher Scientific from $620.00 to $475.00 and set an "equal weight" rating on the stock in a report on Thursday, April 10th. Finally, UBS Group cut their price target on Thermo Fisher Scientific from $715.00 to $500.00 and set a "buy" rating on the stock in a report on Thursday, April 24th. Four investment analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the company's stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $607.43.
Check Out Our Latest Analysis on TMO
Thermo Fisher Scientific Stock Down 0.4%
Shares of TMO traded down $1.67 during trading hours on Wednesday, reaching $401.88. The stock had a trading volume of 1,930,021 shares, compared to its average volume of 1,874,739. Thermo Fisher Scientific Inc. has a 12 month low of $390.50 and a 12 month high of $627.88. The firm has a 50-day simple moving average of $437.74 and a 200 day simple moving average of $502.70. The company has a current ratio of 1.66, a quick ratio of 1.29 and a debt-to-equity ratio of 0.59. The company has a market capitalization of $151.71 billion, a price-to-earnings ratio of 24.31, a P/E/G ratio of 2.99 and a beta of 0.82.
Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last released its quarterly earnings results on Wednesday, April 23rd. The medical research company reported $5.15 EPS for the quarter, beating analysts' consensus estimates of $5.10 by $0.05. The business had revenue of $10.36 billion during the quarter, compared to analyst estimates of $10.23 billion. Thermo Fisher Scientific had a return on equity of 17.51% and a net margin of 14.78%. Thermo Fisher Scientific's quarterly revenue was up .2% compared to the same quarter last year. During the same period in the prior year, the firm posted $5.11 EPS. Equities research analysts predict that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.
Thermo Fisher Scientific Announces Dividend
The business also recently declared a quarterly dividend, which will be paid on Tuesday, July 15th. Investors of record on Friday, June 13th will be given a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a yield of 0.43%. The ex-dividend date of this dividend is Friday, June 13th. Thermo Fisher Scientific's payout ratio is currently 10.09%.
Thermo Fisher Scientific Company Profile
(
Free Report)
Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.
See Also
Before you consider Thermo Fisher Scientific, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Thermo Fisher Scientific wasn't on the list.
While Thermo Fisher Scientific currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
